基于ergosterol纳米脂质体的输送系统的开发,用于对阿尔茨海默氏病的毒性评估和治疗潜力
Himanshu Sharma1, Phool Chandra1
1Department of Pharmacology, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad (UP)-244001, India.
CNS & neurological disorders drug targets
|August 18, 2025
概括
带有厄戈斯特的纳米脂质体 (ER-NL-2) 在阿尔茨海默氏病 (AD) 治疗方面显示出有前途. 这项研究证实了ER-NL-2在动物模型中的安全性,抗氧化能力和神经保护作用,与标准治疗相比.
科学领域:
- 纳米技术纳米技术
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默氏病 (AD) 构成了严重的全球健康挑战,治疗选择有限.
- 厄戈斯特醇具有神经保护和抗氧化特性,但生物利用性较差.
- 开发有效的药物输送系统对于管理AD至关重要.
研究的目的:
- 为了制定和描述带有厄戈斯特的纳米脂质体 (ER-NL-2).
- 评估ER-NL-2在AD动物模型中的安全性,抗氧化潜力和治疗疗效.
- 评估ER-NL-2的神经保护作用,并将其与标准AD疗法进行比较.
主要方法:
- 使用超声波薄膜分散制造的ER-NL-2配方,具有DLS,泽塔电位和TEM的特征.
- 在Wistar大鼠和瑞士小鼠中评估的急性口服毒性.
- 在各自的动物模型中,由链毒素 (STZ) 和AlCl3诱导的AD.
- 进行了行为测试 (actophotometer,升高加迷宫),抗氧化剂测试 (SOD,CAT,GSH,LPO) 和组织病理学分析.
主要成果:
- ER-NL-2的特点是~180nm大小,PDI<0.3和-27.9mV的泽塔电位;球形形态由TEM证实.
- 没有观察到2000mg/kg的毒性.
- 在AD模型中,ER-NL-2改善了运动运动活动,减少了转移延迟,并显示出显著的抗氧化作用 (增加SOD,CAT,GSH;减少LPO).
- 组织病理学发现神经元完整性得到保护,神经纤维状结减少.
结论:
- 在AD模型中,ER-NL-2表现出显著的神经保护和抗氧化疗效,与donepezil相似.
- ER-NL-2是AD治疗的安全纳米载体,显示了进一步临床研究的潜力.
- 需要对ER-NL-2的药理动力学和临床应用进行进一步的研究.
更多相关视频
06:41Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
664
06:52Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
Published on: July 6, 2019
9.4K
相关概念视频
Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261
Alzheimer's Disease: Overview
668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668
